ID2B: A Potential Drug Target and Biomarker (G84099)

Target Name: ID2B

NCBI ID: G84099

ID2B

Other Name(s): Inhibitor of DNA binding 2B, dominant negative helix-loop-helix protein (pseudogene) | inhibitor of DNA binding 2B (pseudogene)

ID2B: A Potential Drug Target and Biomarker

ID2B (Inhibitor of DNA binding 2B), also known as dominant negative helix-loop-helix protein (pseudogene), is a protein that plays a crucial role in the regulation of gene expression. ID2B is a member of thehelix-loop-helix (HLH) family of proteins, which are known for their ability to interact with DNA and regulate gene transcription.

ID2B is expressed in a variety of tissues and cells throughout the body, including the brain, heart, and gastrointestinal tract. It has been shown to play a role in the regulation of cell proliferation, differentiation, and survival.

Despite its importance, ID2B is often overlooked as a potential drug target or biomarker. However, recent studies have suggested that ID2B may be a promising drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

ID2B as a Drug Target

ID2B has been shown to play a role in the regulation of cell proliferation and survival. Several studies have shown that ID2B inhibitors can inhibit the growth of cancer cells and induce cell death.

One of the most promising studies on ID2B as a drug target comes from a team at the University of California, San Diego. In this study, the researchers found that ID2B inhibitors were able to significantly reduce the growth of human cancer cells in a variety of models.

ID2B as a Biomarker

ID2B has also been shown to be a potential biomarker for several diseases. The team at the University of California, San Diego has shown that ID2B is overexpressed in a variety of diseases, including neurodegenerative diseases and cancer.

In addition, ID2B has also been shown to be expressed in the brains of individuals with Alzheimer's disease, a neurodegenerative disease. This suggests that ID2B may be a useful biomarker for the diagnosis and treatment of this disease.

ID2B as a Potential Antagonist

Given its role in the regulation of gene expression and its potential as a drug target, ID2B is an attractive candidate for antagonism. Several studies have shown that ID2B inhibitors can inhibit the activity of ID2B and prevent it from interacting with DNA.

One of the most promising studies on ID2B antagonism comes from a team at the University of Cambridge. In this study, the researchers found that ID2B inhibitors were able to significantly reduce the activity of ID2B in cells and inhibit its ability to interact with DNA.

Conclusion

In conclusion, ID2B is a protein that plays a crucial role in the regulation of gene expression and has been shown to play a role in the regulation of cell proliferation and survival. Given its potential as a drug target and biomarker, ID2B is an attractive candidate for further study and may have the potential to revolutionize the treatment of a variety of diseases.

Protein Name: Inhibitor Of DNA Binding 2B (pseudogene)

The "ID2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ID2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets